Back
$36M IPO
Genenta Science S.p.A. is a clinical-stage biotech company pioneering a one-time cell therapy designed to break tumor-induced immuno suppression by enabling sustained targeted expression of therapeutic payload inside the tumor microenvironment.
At the time of the transaction, Genenta was advancing its lead candidate Temferon™ in glioblastoma (GBM), one of the most aggressive and underserved brain cancers, while laying the foundations for broader application. Genenta aimed to expand the impact of immune-based treatments and strengthen its position among Europe’s emerging oncology innovators.
Building on its prior advisory role for Genenta's Bridge fundraising round, Growth Capital supported the company's management team in strategic choices related to fundraising and listing on Nasdaq.
On December 15th 2021, Genenta listed on Nasdaq, raising around USD 36 million.
Visit website
At the time of the transaction, Genenta was advancing its lead candidate Temferon™ in glioblastoma (GBM), one of the most aggressive and underserved brain cancers, while laying the foundations for broader application. Genenta aimed to expand the impact of immune-based treatments and strengthen its position among Europe’s emerging oncology innovators.
Building on its prior advisory role for Genenta's Bridge fundraising round, Growth Capital supported the company's management team in strategic choices related to fundraising and listing on Nasdaq.
On December 15th 2021, Genenta listed on Nasdaq, raising around USD 36 million.
